2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations

Advanced age, diabetes, and chronic kidney disease not only increase the risk for ischaemic events in chronic coronary syndromes (CCS) but also confer a high bleeding risk during antiplatelet therapy. These special populations may warrant modification of therapy, especially among Asians, who have di...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jack Wei Chieh Tan, Derek P Chew, Kin Lam Tsui, Doreen Tan, Dmitry Duplyakov, Ayman Hammoudeh, Bo Zhang, Yi Li, Kai Xu, Paul J Ong, Doni Firman, Habib Gamra, Wael Almahmeed, Jamshed Dalal, Li-Wah Tam, Gabriel Steg, Quang N Nguyen, Junya Ako, Jassim Al Suwaidi, Mark Chan, Mohamed Sobhy, Abdulla Shehab, Wacin Buddhari, Zulu Wang, Alan Yean Yip Fong, Bilgehan Karadag, Byeong-Keuk Kim, Usman Baber, Chee Tang Chin, Ya Ling Han
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/bffbfa97e42d4e47b8f838fe9e3ad450
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bffbfa97e42d4e47b8f838fe9e3ad450
record_format	dspace
spelling	oai:doaj.org-article:bffbfa97e42d4e47b8f838fe9e3ad4502021-12-04T16:05:18Z2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations10.15420/ecr.2021.351758-37641758-3756https://doaj.org/article/bffbfa97e42d4e47b8f838fe9e3ad4502021-11-01T00:00:00Zhttps://www.ecrjournal.com/articleindex/ecr.2021.35https://doaj.org/toc/1758-3756https://doaj.org/toc/1758-3764Advanced age, diabetes, and chronic kidney disease not only increase the risk for ischaemic events in chronic coronary syndromes (CCS) but also confer a high bleeding risk during antiplatelet therapy. These special populations may warrant modification of therapy, especially among Asians, who have displayed characteristics that are clinically distinct from Western patients. Previous guidance has been provided regarding the classification of high-risk CCS and the use of newer-generation P2Y12 inhibitors (i.e. ticagrelor and prasugrel) after acute coronary syndromes (ACS) in Asia. The authors summarise evidence on the use of these P2Y12 inhibitors during the transition from ACS to CCS and among special populations. Specifically, they present recommendations on the roles of standard dual antiplatelet therapy, shortened dual antiplatelet therapy and single antiplatelet therapy among patients with coronary artery disease, who are either transitioning from ACS to CCS; elderly; or with chronic kidney disease, diabetes, multivessel coronary artery disease and bleeding events during therapy.Jack Wei Chieh TanDerek P ChewKin Lam TsuiDoreen TanDmitry DuplyakovAyman HammoudehBo ZhangYi LiKai XuPaul J OngDoni FirmanHabib GamraWael AlmahmeedJamshed DalalLi-Wah TamGabriel StegQuang N NguyenJunya AkoJassim Al SuwaidiMark ChanMohamed SobhyAbdulla ShehabWacin BuddhariZulu WangAlan Yean Yip FongBilgehan KaradagByeong-Keuk KimUsman BaberChee Tang ChinYa Ling HanRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENEuropean Cardiology Review , Vol 16, Iss , Pp - (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Jack Wei Chieh Tan Derek P Chew Kin Lam Tsui Doreen Tan Dmitry Duplyakov Ayman Hammoudeh Bo Zhang Yi Li Kai Xu Paul J Ong Doni Firman Habib Gamra Wael Almahmeed Jamshed Dalal Li-Wah Tam Gabriel Steg Quang N Nguyen Junya Ako Jassim Al Suwaidi Mark Chan Mohamed Sobhy Abdulla Shehab Wacin Buddhari Zulu Wang Alan Yean Yip Fong Bilgehan Karadag Byeong-Keuk Kim Usman Baber Chee Tang Chin Ya Ling Han 2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations
description	Advanced age, diabetes, and chronic kidney disease not only increase the risk for ischaemic events in chronic coronary syndromes (CCS) but also confer a high bleeding risk during antiplatelet therapy. These special populations may warrant modification of therapy, especially among Asians, who have displayed characteristics that are clinically distinct from Western patients. Previous guidance has been provided regarding the classification of high-risk CCS and the use of newer-generation P2Y12 inhibitors (i.e. ticagrelor and prasugrel) after acute coronary syndromes (ACS) in Asia. The authors summarise evidence on the use of these P2Y12 inhibitors during the transition from ACS to CCS and among special populations. Specifically, they present recommendations on the roles of standard dual antiplatelet therapy, shortened dual antiplatelet therapy and single antiplatelet therapy among patients with coronary artery disease, who are either transitioning from ACS to CCS; elderly; or with chronic kidney disease, diabetes, multivessel coronary artery disease and bleeding events during therapy.
format	article
author	Jack Wei Chieh Tan Derek P Chew Kin Lam Tsui Doreen Tan Dmitry Duplyakov Ayman Hammoudeh Bo Zhang Yi Li Kai Xu Paul J Ong Doni Firman Habib Gamra Wael Almahmeed Jamshed Dalal Li-Wah Tam Gabriel Steg Quang N Nguyen Junya Ako Jassim Al Suwaidi Mark Chan Mohamed Sobhy Abdulla Shehab Wacin Buddhari Zulu Wang Alan Yean Yip Fong Bilgehan Karadag Byeong-Keuk Kim Usman Baber Chee Tang Chin Ya Ling Han
author_facet	Jack Wei Chieh Tan Derek P Chew Kin Lam Tsui Doreen Tan Dmitry Duplyakov Ayman Hammoudeh Bo Zhang Yi Li Kai Xu Paul J Ong Doni Firman Habib Gamra Wael Almahmeed Jamshed Dalal Li-Wah Tam Gabriel Steg Quang N Nguyen Junya Ako Jassim Al Suwaidi Mark Chan Mohamed Sobhy Abdulla Shehab Wacin Buddhari Zulu Wang Alan Yean Yip Fong Bilgehan Karadag Byeong-Keuk Kim Usman Baber Chee Tang Chin Ya Ling Han
author_sort	Jack Wei Chieh Tan
title	2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations
title_short	2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations
title_full	2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations
title_fullStr	2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations
title_full_unstemmed	2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations
title_sort	2021 asian pacific society of cardiology consensus recommendations on the use of p2y12 receptor antagonists in the asia-pacific region: special populations
publisher	Radcliffe Medical Media
publishDate	2021
url	https://doaj.org/article/bffbfa97e42d4e47b8f838fe9e3ad450
work_keys_str_mv	AT jackweichiehtan 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT derekpchew 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT kinlamtsui 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT doreentan 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT dmitryduplyakov 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT aymanhammoudeh 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT bozhang 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT yili 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT kaixu 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT pauljong 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT donifirman 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT habibgamra 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT waelalmahmeed 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT jamsheddalal 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT liwahtam 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT gabrielsteg 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT quangnnguyen 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT junyaako 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT jassimalsuwaidi 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT markchan 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT mohamedsobhy 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT abdullashehab 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT wacinbuddhari 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT zuluwang 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT alanyeanyipfong 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT bilgehankaradag 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT byeongkeukkim 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT usmanbaber 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT cheetangchin 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations AT yalinghan 2021asianpacificsocietyofcardiologyconsensusrecommendationsontheuseofp2y12receptorantagonistsintheasiapacificregionspecialpopulations
_version_	1718372698374012928

2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations

Ejemplares similares